← Therapy pipeline
Investigational · Obesity development

ABBV-295

ABBV295 · AbbVie / Gubra

Investigational long-acting amylin analogue in a Phase 2 dose-finding study.

amylin
Obesity stagePhase 2Updated as of November 2026
SponsorAbbVie / Gubra
Targetsamylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

Phase 2 initiated; numerical Phase 2 results pending.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Long-acting amylin analogueInjection · Study regimen
Phase 2Initiated August 2026; results pending
Milestone → next

Latest: Phase 2 NCT07752979 initiated in August 2026; approximately 360 participants planned.

Next: Week-32 primary weight endpoint; 52-week treatment period. Phase 2 efficacy results pending.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2

ABBV-295 Phase 2 dose-finding

Weight management
Study: OngoingResults: Phase 2 results pendingStatus reviewed November 2026

Approximately 360 adults with obesity or overweight plus a weight-related comorbidity; randomized, double-blind, placebo-controlled; six active treatment arms and placebo. Treatment 52 weeks; primary weight endpoint at week 32.

Related reading: ABBV-295 in the EASD 2026 review ↗